Detalles de la búsqueda
1.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Haematologica
; 105(6): 1604-1612, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537689
2.
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
Haematologica
; 103(8): 1345-1350, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748444
3.
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
Cancers (Basel)
; 14(1)2021 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008372
4.
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
J Clin Oncol
; 39(11): 1214-1222, 2021 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33577377
5.
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Haematol
; 4(1): e15-e23, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27927586
Resultados
1 -
5
de 5
1
Próxima >
>>